Three dimensional (3D) bioprinting has been a powerful tool in patterning and precisely placing biologics, including living cells, nucleic acids, drug particles, proteins and growth factors, to recapitulate tissue anatomy, biology and physiology. Since the first time of cytoscribing cells demonstrated in 1986, bioprinting has made a substantial leap forward, particularly in the past 10 years, and it has been widely used in fabrication of living tissues for various application areas. The technology has been recently commercialized by several emerging businesses, and bioprinters and bioprinted tissues have gained significant interest in medicine and pharmaceutics.
The global 3D bioprinting market is observing significant growth owing to increasing use in the drug discovery process. It offers great precision on spatial placement of cells, proteins, DNA, drug particles, growth factors and biologically active particles to guide tissue generation and formation better. This powerful technology appears to be more promising for advancing tissue fabrication toward physiologically relevant tissue constructs, tissue models, tissues and organs and organs-on-a-chip models for medicine and pharmaceutics. Bioprinting technology has a broad utility in various application areas such as tissue engineering and regenerative medicine, transplantation & clinics, drug screening and high throughput assays and cancer research. With its great advantage in patterning and precisely positioning multiple cell types, bioprinting has evaded one of the major shortcomings of traditional scaffold fabrication techniques and has enabled fabrication of native-like tissues with a heterocellular microenvironment.
The report analyses the global 3D bioprinting market based on technology, material, application and geography.
Based on technology, the market is categorized into magnetic 3D bioprinting, laser-assisted bioprinting, inkjet 3D bioprinting and microextrusion 3D bioprinting. Inkjet-based bioprinting is used in cartilage tissue engineering as well as for cartilage defect repair. The bioprinted cartilage shows mechanical properties and biochemical composition close to natural cartilage.
Various materials of the 3D bioprinting market are extracellular matrices, hydrogels, living cells and other biomaterials including alginate, gelatin, and fibrinogen, among others. Numerous tissue engineering approaches have been applied in skin tissue fabrication and tissue substitutes including autologous split-thickness skin graft (gold standard), allografts, acellular dermal substitutes and cellularized graft-like commercial products.
Furthermore, different applications included this market are categorized into clinical applications such as blood vessels, bone and skin; and research applications such as 3D cell culture, drug and medical research and regenerative medicine. Bone tissue engineering has been widely studied using bioprinting because bioprinting can fabricate anatomically correct patient-specific tissue constructs.
By geography, the global 3D bioprinting market is studied across the countries of key regions such as, North America, Europe, Asia Pacific and rest of the world. In 2018, North America held the largest revenue share mainly due to factors such as government support for quality healthcare, high purchasing power parity and availability of reimbursement. Furthermore, Asia Pacific is expected to witness lucrative growth over the forecast period owing to supportive government initiatives, pioneering presence in healthcare IT development and rapid adoption of the technological innovations. Additionally, economic developments in countries, such as India and China, are expected to help spur the market growth. Huge population base with low per capita income in the region led to high demand for affordable treatment options.
The leading 3D bioprinting market players are Organovo Holdings Inc. (U.S.), EnvisionTEC GmbH (Germany), Nano3D Biosciences, Inc. (U.S.), Cyfuse Biomedical K.K. (Japan), BioBots (U.S.), Aspect Biosystems Ltd. (Canada), 3Dynamic Systems Ltd. (U.K.), regenHU Ltd (Switzerland), Cellink (Sweden), Regenovo Biotechnology Co., Ltd. (China), Poietis (France), and GeSiM (Germany). In January 2019, The Institute for Technology Inspired Regenerative Medicine in Netherlands collaborated with Aspect Biosystems for the advancements in 3D printing and regenerative medicine. In 2018, numerous universities and research institutes have invested in the development of highly efficient and better quality bio-implants at low costs.
The global 3D bioprinting market is segmented based on technology, material, application and geography. Based on technology, the market is categorized into magnetic 3D bioprinting, laser-assisted bioprinting, inkjet 3D bioprinting and microextrusion 3D bioprinting. Inkjet-based bioprinting is used in cartilage tissue engineering as well as for cartilage defect repair.
Various materials of the 3D bioprinting market are extracellular matrices, hydrogels, living cells and other biomaterials including alginate, gelatin, and fibrinogen, among others. Numerous tissue engineering approaches have been applied in skin tissue fabrication and tissue substitutes including autologous split-thickness skin graft (gold standard), allografts, acellular dermal substitutes and cellularized graft-like commercial products.
Furthermore, different applications included this market are categorized into clinical applications such as blood vessels, bone and skin; and research applications such as 3D cell culture, drug and medical research and regenerative medicine.
By geography, the global 3D bioprinting market is studied across the countries of key regions such as, North America, Europe, Asia Pacific and rest of the world. In 2018, North America held the largest revenue share mainly due to factors such as government support for quality healthcare, high purchasing power parity and availability of reimbursement.
Why to buy this report: